Tumor cells cotransfected with interleukin-7 and B7.1 genes induce CD25 and CD28 on tumor-infiltrating T lymphocytes and are strong vaccines

European Journal of Immunology
S CayeuxT Blankenstein

Abstract

Interleukin-7 (IL-7) and the membrane molecule B7 are both able to provide proliferation and activation signals for T cells. However, tumor cells transfected to express either molecule alone are not reliably rejected in syngeneic hosts or are not sufficiently immunogenic to serve as potent tumor vaccines. Since IL-7 and B7 have shown synergistically to induce activation and proliferation of T cells in vitro, we have expressed B7.1 by means of a retrovirus in the mammary adenocarcinoma TS/A which arose spontaneously in a BALB/c mouse and in the plasmacytoma J558L and their IL-7-transfected sublines to improve vaccine efficacy. Expression of IL-7 or B7.1 alone in tumor cells decreased tumorigenicity, but nevertheless tumors grew in a substantial number of mice. In contrast, IL-7/B7.1 cotransfected cells did not grow as tumor in a single case. This inhibition of tumor growth was completely T cell dependent, because TS/A-IL-7/B7.1 cells retained their full tumorigenic potential in T cell-deficient mice. Analysis of tumor-infiltrating T lymphocytes revealed increased numbers of T cells in B7, IL-7 and IL-7/B7 transfected compared to parental tumors. In IL-7/B7 transfected tumors, T cell numbers were not further increased compared to...Continue Reading

References

Dec 1, 1991·The Journal of Experimental Medicine·H HockT Blankenstein
Jan 1, 1992·Proceedings of the National Academy of Sciences of the United States of America·C A MullenR M Blaese
Apr 1, 1991·The Journal of Experimental Medicine·M R AldersonK H Grabstein
May 1, 1991·The Journal of Experimental Medicine·T BlankensteinT Diamantstein
Apr 1, 1990·The Journal of Experimental Medicine·L S ParkA E Namen
Aug 1, 1989·Proceedings of the National Academy of Sciences of the United States of America·G D ChazenE M Shevach
Oct 1, 1983·Clinical & Experimental Metastasis·P NanniG Prodi
Oct 1, 1993·Immunology Today·L ChenK E Hellström
Feb 1, 1994·The Journal of Experimental Medicine·L ChenK E Hellström
Jul 1, 1994·Immunology Today·C H JuneC B Thompson
Jan 1, 1994·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·T Blankenstein
Jun 15, 1993·Proceedings of the National Academy of Sciences of the United States of America·S BaskarL H Glimcher
Oct 1, 1993·Current Opinion in Immunology·D M Pardoll
Jan 1, 1994·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·A G Dalgleish
Feb 1, 1994·Human Gene Therapy·R I Tepper, J J Mulé
Jan 1, 1993·Annual Review of Immunology·P S Linsley, J A Ledbetter
Apr 1, 1993·European Journal of Immunology·S Krüger-KrasagakesT Blankenstein
Apr 1, 1993·The Journal of Experimental Medicine·J ConnorE Gilboa
Apr 1, 1993·Proceedings of the National Academy of Sciences of the United States of America·H HockT Blankenstein

❮ Previous
Next ❯

Citations

Sep 30, 2000·Stem Cells·L CaoF M Rosenthal
Sep 1, 1996·Cancer Metastasis Reviews·R G Vile, H Chong
Jan 1, 1996·Springer Seminars in Immunopathology·H Chong, R G Vile
Sep 1, 1997·Urologic Oncology·N NishisakaG P Haas
Nov 14, 1997·Immunotechnology : an International Journal of Immunological Engineering·H O Sjögren
May 26, 1998·Scandinavian Journal of Immunology·B B PonnerM Herrmann
Oct 1, 1996·Journal of Hematotherapy·A DwengerR Mertelsmann
Apr 21, 2005·The Journal of Clinical Investigation·Fraia MelchiondaCrystal L Mackall
Feb 14, 2004·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·M A A Al-RawiW G Jiang
Jan 26, 2012·Biotechnology and Bioengineering·Nick X WangHorst A von Recum
Jan 1, 1997·International Reviews of Immunology·C Viret, A Lindemann
Feb 1, 1997·Annals of Medicine·L S Lashford
Jul 16, 2008·Expert Opinion on Therapeutic Targets·Manzoor A Mir, Javed N Agrewala
Mar 17, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Markus Y Mapara, Megan Sykes
Mar 10, 2005·International Journal of Cancer. Journal International Du Cancer·Lilian StärckPeter T Daniel
Mar 30, 2001·Cell Death and Differentiation·C M StachM Herrmann
May 16, 2002·Blood·Terry J Fry, Crystal L Mackall
Mar 10, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·T F Greten, E M Jaffee
Apr 21, 1999·International Journal of Cancer. Journal International Du Cancer·S HallezO Leo
Dec 19, 1998·Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research·P C EmtageJ Gauldie

❮ Previous
Next ❯

Related Concepts

Related Feeds

Avian Influenza: Innate Immune Adjuvant

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Avian Influenza: Innate Immune Adjuvant (ASM)

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.

Related Papers

Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte
R MertelsmannH Veelken
European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)
T Blankenstein
Proceedings of the National Academy of Sciences of the United States of America
W SchmidtM L Birnstiel
© 2021 Meta ULC. All rights reserved